Table 1

Baseline characteristics

DabigatranDabigatranRivaroxabanRivaroxabanApixabanApixabanWarfarin
150 mg two times per day110 two times per day20 mg once a day15 mg once a day5 mg two times per day2.5 mg two times per day2.5 mg
N931292636302478763161556650
Year of inclusion into study
 2013356 (38.2)1 333 (45.6)902 (24.8)724 (29.2)93 (1.2)87 (1.4)3131 (47.1)
 2014284 (30.5)837 (28.6)834 (23.0)653 (26.4)846 (11.1)846 (13.7)1868 (28.1)
 2015116 (12.5)296 (10.1)755 (20.8)539 (21.8)1780 (23.3)1546 (25.1)951 (14.3)
 201688 (9.5)224 (7.7)680 (18.7)362 (14.6)2303 (30.2)1916 (31.1)485 (7.3)
 201787 (9.3)236 (8.1)459 (12.6)200 (8.1)2609 (34.2)1760 (28.6)215 (3.2)
Age
 75–84875 (94.0)1867 (63.8)2764 (76.1)1279 (51.6)6020 (78.9)2643 (42.9)4186 (62.9)
 85–9453 (5.7)1020 (34.9)845 (23.3)1122 (45.3)1560 (20.4)3254 (52.9)2379 (35.8)
 95–1053 (0.3)39 (1.3)21 (0.6)77 (3.1)51 (0.7)258 (4.2)85 (1.3)
 Mean (SD)78.0 (3.5)83.0 (4.9)81.0 (4.8)84.4 (5.4)80.8 (4.6)85.6 (5.3)82.9 (5.1)
 Median (25th–75th percentile)77 (76–79)82 (79–86)80 (77–84)84 (80–88)80 (77–84)86 (82–89)82 (79–87)
Female gender386 (41.5)1633 (55.8)1812 (49.9)1401 (56.5)3744 (49.1)3818 (62.0)3316 (49.9)
Hypertension619 (66.5)2194 (75.0)2566 (70.7)1971 (79.5)5521 (72.3)4741 (77.0)5235 (78.7)
Ischaemic heart disease186 (20.0)764 (26.1)831 (22.9)750 (30.3)1874 (24.6)1920 (31.2)2511 (37.8)
Peripheral artery disease73 (7.8)289 (9.9)366 (10.1)267 (10.8)796 (10.4)722 (11.7)898 (13.5)
Heart failure160 (17.2)902 (30.8)830 (22.9)982 (39.6)1979 (25.9)2490 (40.5)2904 (43.7)
Chronic kidney disease20 (2.1)146 (5.0)119 (3.3)311 (12.6)387 (5.1)1065 (17.3)1096 (16.5)
Diabetes mellitus114 (12.2)377 (12.9)485 (13.4)348 (14.0)1117 (14.6)962 (15.6)1187 (17.8)
Thyroid disorders32 (3.4)151 (5.2)146 (4.0)143 (5.8)321 (4.2)333 (5.4)385 (5.8)
Chronic lower234 (25.1)707 (24.2)944 (26.0)600 (24.2)2081 (27.3)1639 (26.6)1760 (26.5)
respiratory tract disorder
Active cancer (diagnosis last 12 months91 (9.8)283 (9.7)375 (10.3)277 (11.2)823 (10.8)715 (11.6)745 (11.2)
Dementia12 (1.3)88 (3.0)92 (2.5)94 (3.8)187 (2.5)276 (4.5)203 (3.1)
History of stroke/SE136 (14.6)528 (18.0)600 (16.5)411 (16.6)1253 (16.4)1117 (18.1)1096 (16.5)
History of ischaemic stroke134 (14.4)512 (17.5)588 (16.2)394 (15.9)1229 (16.1)1087 (17.7)1069 (16.1)
History of intracranial haemorrhage3 (0.3)27 (0.9)21 (0.6)23 (0.9)50 (0.7)67 (1.1)45 (0.7)
History of bleeding105 (11.3)448 (15.3)501 (13.8)432 (17.4)1106 (14.5)1273 (20.7)1225 (18.4)
History of gastrointestinal bleeding23 (2.5)131 (4.5)143 (3.9)143 (5.8)297 (3.9)372 (6.0)399 (6.0)
History of anaemia41 (4.4)237 (8.1)236 (6.5)276 (11.1)614 (8.0)812 (14.8)788 (11.8)
Use of antiplatelet drugs last 12 months494 (53.1)1789 (61.1)2127 (58.6)1581 (63.8)4384 (57.4)3830 (62.2)3803 (57.2)
Use of NSAIDs last 12 months242 (26.0)590 (20.2)770 (21.2)451 (18.2)1584 (20.8)987 (16.0)1128 (17.0)
Use of cholesterol lowering drugs461 (49.5)1463 (50.0)1770 (48.8)1264 (51.0)4107 (53.8)3174 (51.6)3735 (56.2)
Mean CHA2DS2-VaSc score (SD)3.9 (1.3)4.4 (1.4)4.2 (1.3)4.6 (1.4)4.3 (1.3)4.7 (1.4)4.7 (1.4)
Mean HAS-BLED score (SD)2.6 (0.95)2.8 (0.9)2.7 (0.95)3.0 (1.0)2.8 (0.98)3.0 (1.1)2.9 (1.0)
  • Values are numbers (per cent), unless otherwise stated.

  • CHA2DS2-VaSc, congestive heart failure (or left ventricular systolic dysfunction), hypertension, age ≥75 years, diabetes mellitus, prior stroke or transient ischaemic attack or systemic embolism, vascular disease, age ≥65 years, sex category; HAS-BLED, hypertension, abnormal renal function/ abnormal liver function, prior stroke, prior major bleeding, labile international normalised ratio (INR), elderly age ≥65 years, prior alcohol or drug abuse/use of medications that predispose to bleeding (antiplatelet agents, NSAIDs); NSAIDs, non-steroidal anti-inflammatory drugs; SE, systemic embolism.